

# Androgen receptor, a target for prostate cancer treatment, imports into mitochondria and plays a novel role

March 19 2019, by Jeff Hansen

---



Keshav K. Singh, Ph.D. Credit: University of Alabama at Birmingham

Androgens, commonly known as male hormones, stimulate prostate cancer cells to grow. Thus, many of the drugs to target that cancer focus on stopping androgen biosynthesis or blocking the androgen receptor. This standard treatment is known as androgen deprivation therapy.

However, patients can develop resistance to this therapy and progress to androgen-independent, or castration-resistant, [prostate](#) cancer. This form is challenging to treat, which is one of the reasons prostate cancer is the second-leading cause of cancer deaths in men.

The androgen receptor, or AR, is a cellular protein in prostate tissues that is activated by binding androgen hormones like testosterone. The AR then moves to the cell nucleus to regulate the transcription of a host of genes. In prostate [cancer](#), mutations in the AR can make it able to regulate transcription without the need to bind [androgen](#).

Researchers at the University of Alabama at Birmingham have discovered a new function of the AR in prostate cells—the AR is imported into and localizes to [mitochondria](#) of the cell, where it plays a novel role in regulating multiple [mitochondrial](#) processes. Mitochondria, located in the cytosol of the cells, are the powerhouses of the cell. Many mitochondria in each cell work to produce approximately 90 percent of the energy cells need to survive.

The cell's DNA genome is located inside the [cell nucleus](#); but human mitochondria, with 37 genes, and the human nucleus, with 20,000 genes, engage in intricate, yet poorly understood, cross-talk that helps to fine-tune cellular metabolism.

The UAB study, led by Keshav K. Singh, Ph.D., professor of genetics in the UAB School of Medicine and a senior scientist in the O'Neal Comprehensive Cancer Center at UAB, provides a new element of mitonuclear cross-talk that may be interesting because several studies have linked AR and mitochondria independently to [prostate cancer](#) risk, aggressiveness and outcome.

In detail, Singh and colleagues found that the AR localized to mitochondria in prostate tissues, and prostate cell lines, and it could be

imported into mitochondria in vitro. Import of AR was dependent on a 36-amino-acid-long mitochondrial localization sequence that his team found on the AR; deletion of that sequence abolished import.

Using cell constructs that either knocked down or expressed AR, the researchers saw an inverse relationship between AR expression and mitochondrial DNA content and the amounts of a mitochondrial transcription factor called TFAM, which regulates mitochondrial DNA content.

Expression of AR reduced the expression of oxidative phosphorylation subunits, destabilized oxidative phosphorylation supercomplexes and reduced oxidative phosphorylation enzymatic activities. Moreover, mitochondrial impairment induced AR expression and increased its translocation into mitochondria.

**More information:** Prachi Bajpai et al. Mitochondrial localization, import and mitochondrial function of the androgen receptor, *Journal of Biological Chemistry* (2019). [DOI: 10.1074/jbc.RA118.006727](https://doi.org/10.1074/jbc.RA118.006727)

Provided by University of Alabama at Birmingham

Citation: Androgen receptor, a target for prostate cancer treatment, imports into mitochondria and plays a novel role (2019, March 19) retrieved 3 March 2023 from <https://medicalxpress.com/news/2019-03-androgen-receptor-prostate-cancer-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.